Extended Data Fig. 1: Treatment and surgery summary in patients with stage III N2 and non-N2 NSCLC.
Neoadjuvant treatment, surgery, and adjuvant treatment by treatment arm and N2 status in all randomized patients. The denominators used to calculate percentages were based on patients in each N2 or non-N2 subgroup. aOne patient in the nivolumab N2 subgroup, 1 patient in the nivolumab non-N2 subgroup, 2 patients in the placebo N2 subgroup, and 1 patient in the placebo non-N2 subgroup did not undergo definitive surgery but did receive adjuvant treatment. AE, adverse event.
